The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The economic burden of prostate cancer
Abstract
What's known on the subject? and What does the study add? Prostate cancer is the most common malignancy in men. Treatment is costly; the majority of men are treated with radiation or surgery, but even watchful waiting strategies are expensive. With increasing life expectancy more men are being diagnosed with prostate cancer, effectively increasing the economic burden of this disease. This study provides estimates of the cost of prostate cancer for different countries. These estimates could be used to populate models that explore economic costs of treating and preventing prostate cancer. Our review found considerable variation in costs across different countries, which may be due to differences in detection and management practices. In the present review we discuss expenditure on prostate cancer diagnosis, treatment and follow‐up and evaluate the cost of prostate cancer and its management in different countries. Prostate cancer costs were identified from published data and internet sources. To provide up‐to‐date comparisons, costs were inflated to 2010 levels and the most recent exchange rates were applied. A high proportion of the costs are incurred in the first year after diagnosis; in 2006, this amounted to 106.7–179.0 million euros (€) in the European countries where these data were available (UK, Germany, France, Italy, Spain and the Netherlands). In the USA, the total estimated expenditure on prostate cancer was 9.862 billion US dollars ($) in 2006. The mean annual costs per patient in the USA were $10 612 in the initial phase after diagnosis, $2134 for continuing care and $33 691 in the last year of life. In Canada, hospital and drug expenditure on prostate cancer totalled C$103.1 million in 1998. In Australia, annual costs for prostate cancer care in 1993–1994 were 101.1 million Australian dollars. Variations in costs between countries were attributed to differences in incidence and management practices. Per patient costs depend on cancer stage at diagnosis, survival and choice of treatment. Despite declining mortality rates, costs are expected to rise owing to increased diagnosis, diagnosis at an earlier stage and increased survival. Unless new strategies are devised to increase the efficiency of healthcare provision, the economic burden of prostate cancer will continue to rise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Cited by
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0650 · Cited by 503
Economic Burden of Cancer Survivorship Among Adults in the United States
Guy, G. P., Ekwueme, D. U., Yabroff, K. R., Dowling, E. C., Li, C., Rodriguez, J. L., de Moor, J. S., & Virgo, K. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1241 · Cited by 351
Real-world data: towards achieving the achievable in cancer care
Booth, C. M., Karim, S., & Mackillop, W. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0167-7 · Cited by 327
Murtojärvi, M., Halkola, A. S., Airola, A., Laajala, T. D., Mirtti, T., Aittokallio, T., & Pahikkala, T. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.104014 · Cited by 14
Metadata
- Authors
- Roehrborn, C. G., & Black, L. K.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2011-08-25
- Volume
- 108
- Issue
- 6
- Pages
- 806-813
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1504213150
- Cited by
- 199
- References
- 1
- FWCI
- 33.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The economic burden of prostate cancer. https://app.cochat.ai/papers/10.1111/j.1464-410x.2011.10365.x
- The paper
- Roehrborn, C. G., & Black, L. K. (2011). The economic burden of prostate cancer. BJU International. https://doi.org/10.1111/j.1464-410x.2011.10365.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.